[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EG25542A - Oral dosge forms for propiverne or pharmaceutically acceptable salts thereof having prolonged release of the active agent - Google Patents

Oral dosge forms for propiverne or pharmaceutically acceptable salts thereof having prolonged release of the active agent

Info

Publication number
EG25542A
EG25542A EG2002101109A EG2002101109A EG25542A EG 25542 A EG25542 A EG 25542A EG 2002101109 A EG2002101109 A EG 2002101109A EG 2002101109 A EG2002101109 A EG 2002101109A EG 25542 A EG25542 A EG 25542A
Authority
EG
Egypt
Prior art keywords
propiverne
dosge
oral
forms
pharmaceutically acceptable
Prior art date
Application number
EG2002101109A
Other languages
English (en)
Inventor
Thomas Gramatte
Peter Gruber
Peter Guldner
Michael Heschel
Dirk Pamperin
Jan Ploen
Steffen Scheithauer
Wolfgang Wehner
Original Assignee
Apogepha Arzneimittel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogepha Arzneimittel Gmbh filed Critical Apogepha Arzneimittel Gmbh
Application granted granted Critical
Publication of EG25542A publication Critical patent/EG25542A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/06Anti-spasmodics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EG2002101109A 2001-10-09 2002-10-09 Oral dosge forms for propiverne or pharmaceutically acceptable salts thereof having prolonged release of the active agent EG25542A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10149674A DE10149674A1 (de) 2001-10-09 2001-10-09 Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung

Publications (1)

Publication Number Publication Date
EG25542A true EG25542A (en) 2012-02-14

Family

ID=7701848

Family Applications (1)

Application Number Title Priority Date Filing Date
EG2002101109A EG25542A (en) 2001-10-09 2002-10-09 Oral dosge forms for propiverne or pharmaceutically acceptable salts thereof having prolonged release of the active agent

Country Status (33)

Country Link
US (1) US7943176B2 (sh)
EP (1) EP1435915B1 (sh)
JP (1) JP4192096B2 (sh)
KR (1) KR100723964B1 (sh)
CN (1) CN100473382C (sh)
AR (1) AR036768A1 (sh)
AT (1) ATE401865T1 (sh)
AU (1) AU2002346973B8 (sh)
CA (1) CA2462482C (sh)
CY (1) CY1108426T1 (sh)
DE (2) DE10149674A1 (sh)
DK (1) DK1435915T3 (sh)
EA (1) EA008862B1 (sh)
EG (1) EG25542A (sh)
ES (2) ES2311068T3 (sh)
HK (1) HK1067310A1 (sh)
HR (1) HRP20040323C1 (sh)
HU (1) HU227878B1 (sh)
IL (2) IL160977A0 (sh)
IS (1) IS2571B (sh)
JO (1) JO2555B1 (sh)
ME (2) ME00327B (sh)
MX (1) MXPA04003132A (sh)
MY (1) MY142403A (sh)
PE (1) PE20030399A1 (sh)
PL (1) PL208229B1 (sh)
PT (1) PT1435915E (sh)
RS (1) RS50924B (sh)
SI (1) SI1435915T1 (sh)
TW (1) TWI315204B (sh)
UA (1) UA75727C2 (sh)
WO (1) WO2003030869A1 (sh)
ZA (1) ZA200402437B (sh)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10209982A1 (de) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
ATE549015T1 (de) * 2003-10-31 2012-03-15 Hexal Ag Pharmazeutische wirkstoffhaltige formulierung mit überzug
DE10353196A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
DE10353186A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
EP3216449A1 (en) * 2003-11-14 2017-09-13 EA Pharma Co., Ltd. Oral administration preparation of phenylalanine derivatives
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
WO2006046560A1 (ja) * 2004-10-29 2006-05-04 Taiho Pharmaceutical Co., Ltd. プロピベリン含有経口粉粒状製剤及びその製造法
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2599937A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
EP1863460B1 (en) 2005-03-22 2013-01-16 Losan Pharma GmbH Solubilized ibuprofen
EP1863453A2 (en) * 2005-03-29 2007-12-12 Evonik Röhm GmbH Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
EP1868580A1 (en) * 2005-03-29 2007-12-26 Evonik Röhm GmbH Multiparticulate pharmaceutical form comprising pellets with a matrix which influences the delivery of a modulatory substance
CA2608363A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
PL1912650T3 (pl) * 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Zastosowanie flibanseryny w leczeniu otyłości
WO2007048803A1 (en) * 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
KR20140088230A (ko) 2006-01-27 2014-07-09 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
CN103211779B (zh) * 2006-01-27 2016-03-16 阿代尔制药股份有限公司 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
LT3095447T (lt) 2006-02-03 2022-02-10 Opko Renal, Llc Vitamino d nepakankamumo ir stokos gydymas 25-hidroksivitaminu d2 ir 25-hidroksivitaminu d3
PE20080090A1 (es) * 2006-05-09 2008-03-14 Boehringer Ingelheim Int Flibanserina para el tratamiento de trastornos post-menopausicos del deseo sexual
DK2037936T3 (da) 2006-06-21 2014-09-22 Opko Renal Llc Fremgangsmåde til behandling og forebyggelse af sekundær hyperparathyroidisme
US20090312242A1 (en) * 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
US20090318469A1 (en) * 2006-07-14 2009-12-24 Boehringer Ingelheim International Gmbh Use of Flibanserin for the Treatment of Sexual Disorders in Females
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
KR20090042967A (ko) 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법
EP2056797A2 (en) * 2006-08-25 2009-05-13 Boehringer Ingelheim International GmbH Controlled release system and method for manufacturing the same
MX2009002166A (es) 2006-08-31 2009-03-12 Eurand Inc Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos.
CA2678367C (en) * 2007-03-02 2014-07-08 Farnam Companies, Inc. Sustained release compositions using wax-like materials
JP2010523476A (ja) 2007-03-08 2010-07-15 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ ミトコンドリアアルデヒドデヒドロゲナーゼ−2モジュレーター及びその使用方法
WO2008116890A2 (en) * 2007-03-28 2008-10-02 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
ES2401205T3 (es) 2007-04-25 2013-04-17 Cytochroma Inc. Composiciones de orales de liberación controlada que comprende un compuesto de vitamina D y un soporte céreo
DK2148684T3 (da) 2007-04-25 2013-04-22 Cytochroma Inc Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
KR101500792B1 (ko) * 2008-01-10 2015-03-09 에보니크 룀 게엠베하 결장에서 증가된 활성 물질 방출을 갖는 코팅된 제약학적 또는 건강기능성 제제
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
WO2010028175A1 (en) * 2008-09-08 2010-03-11 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
JP2012506856A (ja) 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
CA2797537C (en) 2010-03-29 2021-11-23 Cytochroma Inc. Use of 25-hydroxyvitamin d compound for reducing parathyroid levels
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
WO2012154892A1 (en) * 2011-05-10 2012-11-15 Theravida, Inc. Combinations of propiverine and salivary stimulants for the treatment of overactive bladder
CN102579404A (zh) * 2012-01-17 2012-07-18 广州科的信医药技术有限公司 一种盐酸丙哌维林缓释胶囊及其制备方法
CN102743756A (zh) * 2012-07-24 2012-10-24 兆科药业(广州)有限公司 一种盐酸丙哌维林与α受体拮抗剂复方制剂
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−2調節因子およびその使用方法
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 d 방출 제형
US10751287B2 (en) * 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
TR201801650T1 (tr) 2015-08-07 2018-03-21 Santa Farma Ilac Sanayii Anonim Sirketi Kontrollü salim propi̇veri̇n formülasyonlari
MX2018011820A (es) 2016-03-28 2019-01-24 Opko Ireland Global Holdings Ltd Metodos de tratamiento con vitamina d.
EP3796908B1 (en) 2018-11-16 2023-05-10 Santa Farma Ilaç Sanayi A.S. Controlled release propiverine formulations
TR201918013A2 (tr) * 2019-11-19 2021-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Propi̇veri̇n veya propi̇veri̇ni̇n farmasöti̇k olarak kabul edi̇lebi̇li̇r bi̇r tuzunu i̇çeren pellet kompozi̇syonu
EP4061369A4 (en) * 2019-11-19 2024-04-10 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi PHARMACEUTICAL FORM COMPRISING AN ACIDIC SUBSTANCE
CN112152871B (zh) * 2020-08-14 2021-09-24 上海纽盾科技股份有限公司 网络安全设备的人工智能测试方法、装置及系统
EP4251154A4 (en) 2020-11-27 2024-07-31 Santa Farma Ilac Sanayii A S SUSTAINED-RELEASE FORMULATION COMPOSITIONS COMPRISING PROPIVERINE
WO2023128906A1 (en) * 2021-12-30 2023-07-06 Santa Farma Ilac Sanayii A.S. Release of propiverine compositions in gastric conditions

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD139212A1 (de) * 1978-10-09 1979-12-19 Christian Starke Verfahren zur herstellung eines neuen arzneimittels aus alpha,alpha-diphenyl-alpha-alkoxyessigsaeure-1-methylpiperidyl-4-ester-derivaten
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
GB8616669D0 (en) 1986-07-09 1986-08-13 Merk Sharpe & Dohme Ltd Pharmaceutical compositions
JPS63154619A (ja) 1986-12-17 1988-06-27 Kowa Yakuhin Kogyo Kk 頻尿および残尿感治療剤
SE8803822D0 (sv) 1988-10-26 1988-10-26 Novel dosage form
US5178868A (en) * 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form
US5368861A (en) 1989-10-26 1994-11-29 Nippon Shinyaku Co., Ltd. Gastric preparation with sustained release
US5399359A (en) 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
WO1996012477A1 (en) 1994-10-21 1996-05-02 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5674895A (en) 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US5811126A (en) 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
ZA97976B (en) 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.
US6190591B1 (en) 1996-10-28 2001-02-20 General Mills, Inc. Embedding and encapsulation of controlled release particles
US5788987A (en) 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
OA11636A (en) 1998-08-27 2004-09-03 Pharmacia Ab Therapeutic formulation for administering tolterodine with controlled release.
US6180136B1 (en) 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
EP1146862B1 (de) 1999-01-29 2003-04-23 Disphar International B.V. Pharmazeutische zusammensetzungen
EP1064938A1 (en) 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
JP2001039873A (ja) 1999-08-02 2001-02-13 Nichiban Co Ltd 経皮吸収型排尿障害治療剤
WO2001032149A1 (en) 1999-10-29 2001-05-10 Merck & Co., Inc. Osmotic controlled release drug delivery device
EP1229026A4 (en) * 1999-11-10 2003-09-24 Takeda Chemical Industries Ltd ALKOXYIMINOALKANSÄURE DERIVATIVES
JP2001048783A (ja) 2000-01-01 2001-02-20 Lead Chemical Co Ltd 経皮吸収型頻尿・尿失禁治療剤
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
JP2003523382A (ja) * 2000-02-24 2003-08-05 ファルマシア・アンド・アップジョン・カンパニー 新規な薬物の組合せ
DE10016356B4 (de) * 2000-04-03 2007-06-21 Beisel, Günther Mittel mit verbesserter Retardwirkung und Verfahren zu dessen Herstellung
IL151150A0 (en) * 2001-01-31 2003-04-10 Roehm Gmbh Multiparticulate drug form comprising at least two differently coated pellet forms
IL151151A0 (en) * 2001-02-27 2003-04-10 Roehm Gmbh Coating and binding agent for pharmaceutical formulations having improved storage stability
ITMI20011446A1 (it) 2001-07-06 2003-01-06 Altergon Sa Composizioni farmaceutiche di principi attivi suscettibili di somministrazione illecita
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung

Also Published As

Publication number Publication date
UA75727C2 (en) 2006-05-15
YU28104A (sh) 2006-08-17
IS2571B (is) 2010-01-15
PE20030399A1 (es) 2003-05-08
JP4192096B2 (ja) 2008-12-03
DE50212546D1 (de) 2008-09-04
AR036768A1 (es) 2004-09-29
CY1108426T1 (el) 2014-04-09
AU2002346973B2 (en) 2006-10-12
MEP44308A (en) 2011-02-10
IL160977A0 (en) 2004-08-31
KR20050034589A (ko) 2005-04-14
SI1435915T1 (sl) 2008-12-31
EA200400471A1 (ru) 2004-10-28
ES2299287B1 (es) 2009-10-14
MXPA04003132A (es) 2005-01-25
PL208229B1 (pl) 2011-04-29
CA2462482A1 (en) 2003-04-17
JP2005505589A (ja) 2005-02-24
PT1435915E (pt) 2008-10-30
ATE401865T1 (de) 2008-08-15
PL368301A1 (en) 2005-03-21
MY142403A (en) 2010-11-30
ES2299287A1 (es) 2008-05-16
CN100473382C (zh) 2009-04-01
TWI315204B (en) 2009-10-01
CA2462482C (en) 2010-02-16
RS50924B (sr) 2010-08-31
US20040258749A1 (en) 2004-12-23
US20080317848A2 (en) 2008-12-25
ES2311068T3 (es) 2009-02-01
ZA200402437B (en) 2004-09-06
US7943176B2 (en) 2011-05-17
DE10149674A1 (de) 2003-04-24
DK1435915T3 (da) 2008-11-24
HRP20040323A2 (en) 2004-08-31
HK1067310A1 (en) 2005-04-08
JO2555B1 (en) 2010-09-05
ME00327B (me) 2011-02-10
KR100723964B1 (ko) 2007-06-04
IS7192A (is) 2004-03-19
HUP0401714A2 (hu) 2004-12-28
AU2002346973B8 (en) 2006-11-09
HU227878B1 (en) 2012-05-29
HRPK20040323B3 (en) 2005-12-31
HUP0401714A3 (en) 2006-01-30
CN1638737A (zh) 2005-07-13
IL160977A (en) 2008-11-26
EP1435915A1 (de) 2004-07-14
HRP20040323C1 (hr) 2013-11-08
EP1435915B1 (de) 2008-07-23
EA008862B1 (ru) 2007-08-31
WO2003030869A1 (de) 2003-04-17

Similar Documents

Publication Publication Date Title
EG25542A (en) Oral dosge forms for propiverne or pharmaceutically acceptable salts thereof having prolonged release of the active agent
AU2002346973A1 (en) Oral Dosage Form for Propiverine or its Pharmaceutically Acceptable Salts with an Extended Release of the Active Ingredient
HK1034183A1 (en) Galenic formulations of meloxicam for oral administration.
EP1383376A4 (en) PHARMACEUTICAL FORMULATIONS WITH PROLONGED RELEASE
HUP0301921A3 (en) Sustained release pharmaceutical compositions for paranteral administration of hydrophilic compounds
MXPA03002569A (es) Formulaciones de liberacion controlada para administracion oral.
AU2001248336A1 (en) Controlled release oral solid forms containing mesalazine as active agent
GB0107751D0 (en) Pharmaceutically active compounds
GB0105893D0 (en) Pharmaceutically active compounds
GB0106631D0 (en) Pharmaceutically active compounds
HK1063798A1 (en) Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers
IL155431A0 (en) Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders
HUP0401599A3 (en) Extended release oral dosage form
IL150403A0 (en) NOVEL PROCESS FOR THE PREPARATION OF α-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
EP1357898A4 (en) ORAL DOSAGE FORM WITH ENHANCED REGULATED RELEASE
PT1576951E (pt) Formulações para administração rectal de agentes com acção trombolitica
HUP0302982A3 (en) Crystalline therapeutic agent
AU2002348105A1 (en) Oral dosage forms for improving the bioavailability of therapeutic agents
GB0017822D0 (en) Pharmaceutically active compound
IL150402A0 (en) NOVEL PROCESS FOR THE PREPARATION OF α-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
GB0106629D0 (en) Pharmaceutically active compounds
GB0106562D0 (en) Pharmaceutically active compounds
GB0106651D0 (en) Pharmaceutically active compounds
GB0106617D0 (en) Pharmaceutically active compounds
GB0106561D0 (en) Pharmaceutically active compounds